A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumours.

Trial Profile

A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Cabozantinib (Primary) ; Rosiglitazone
  • Indications Renal cancer; Solid tumours; Thyroid cancer
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2012 Interim results from a cohort of renal cell carcinoma patients have been presented at ASCO-2012 according to an Exelixis media release. Results were also summarised in the media release.
    • 24 May 2012 Planned end date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top